Kala Bio Hires Dr. Saeid Babaei as Senior Scientific Advisor to Evaluate Clinical Assets and Precision Development Opportunities
ByAinvest
Wednesday, Apr 1, 2026 6:46 am ET1min read
KALA--
Kala Bio has engaged Dr. Saeid Babaei as a Senior Scientific Advisor to evaluate clinical assets and precision development opportunities. The focus will be on applying AI-enabled analytics and digital health tools to Kala's MSC Secretome platform. The aim is to unlock value through amended indications, assess hypotheses related to potential responder subgroups, and develop a regulatory-conscious analytical framework. The collaboration marks a pivotal step in Kala Bio's strategy to maximize commercial and scientific value.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet